Table 1 Baseline characteristics
From: Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Baseline features (n = 27) | N (%) |
|---|---|
Median age, years (range) | 69 (47–85) |
Male | 23 (85) |
≥2 prior therapies | 20 (74) |
Organ dysfunction | |
Renal dysfunction | 17 (63) |
Hepatic dysfunction | 7 (26) |
Cardiac dysfunction | 11 (41) |
2 organ dysfunctions | 8 (30) |
Received nivolumab | 16 (59) |
Median number of doses (range) | 7 (1–52) |
Disease state | |
Renal cell carcinoma | 8 (30 %) |
Melanoma | 10 (37 %) |
Non-small cell lung cancer | 3 (11 %) |
Small cell lung cancer | 2 (7 %) |
Urothelial cell carcinoma | 4 (15 %) |